# Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies

> **NCT03961555** · PHASE2 · COMPLETED · sponsor: **Synermore Biologics Co., Ltd.** · enrollment: 448 (actual)

## Conditions studied

- Rabies

## Interventions

- **BIOLOGICAL:** SYN023
- **BIOLOGICAL:** HRIG (HyperRab)
- **BIOLOGICAL:** Rabies vaccine

## Key facts

- **NCT ID:** NCT03961555
- **Lead sponsor:** Synermore Biologics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-03
- **Primary completion:** 2021-12-23
- **Final completion:** 2021-12-23
- **Target enrollment:** 448 (ACTUAL)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961555, "Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03961555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*